Extended use for Remicade in Crohn's disease

Coloured X-ray of the intestine in Crohn’s disease | SCIENCE PHOTO LIBRARY
Coloured X-ray of the intestine in Crohn’s disease | SCIENCE PHOTO LIBRARY

Approval for the use of Remicade (infliximab) in Crohn’s disease has been extended to include moderately active disease.

The licence extension is based on the results of the double-blind . Investigators randomised 508 adults with moderate to severe Crohn’s disease to receive infliximab, azathioprine, or infliximab plus azathioprine.

After 26 weeks, the rate of corticosteroid-free clinical remission was higher among the patients who received infliximab (44.4%) or combination therapy (56.8%) than among those who were given azathioprine only (30.0%; p=0.006 and p<0.001, respectively). Rates of mucosal healing were also significantly greater in the 2 infliximab groups than in the azathioprine-only group.

Dosing of infliximab in moderate Crohn’s disease is the same as for severe disease.

View Remicade drug record

Further Information: Schering-Plough


Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

Cases of necrotising fasciitis of the genitalia or...

New advice for carbimazole over malformation and pancreatitis risks

New advice for carbimazole over malformation and pancreatitis risks

Reports of congenital malformations and acute pancreatitis...

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.